Targeting sphingosine kinase 1 in cancer

Advances in Biological Regulation

Volumn 52, Issue 1, 2012, Pages 31-38

  Pyne, Nigel J ^a   Tonelli, Francesca ^a   Lim, Keng Gat ^a   Long, Jaclyn ^a   Edwards, Joanne ^b   Pyne, Susan ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865654249     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2011.07.001     Document Type: Review

References (41)

1. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine 1-phosphate is a missing co-factor for the E3 ligase TRAF2. Nature 2010, 465:1084-1088.
2. Baran Y., Salas A., Senkal C.E., Gunduz U., Bielawski J., Obeid L.M., et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib induced apoptosis in K562 human chronic myeloid lekaemia cells. J Biol Chem 2009, 282:10922-10934.
3. Billich A., Bornacin F., Devay P., Mechtcheriakova D., Urtz N., Baumruker T. Phosphorylation of the immunomofulatory drug, FTY720 by sphingosine kinase. J Biol Chem 2003, 278:47,408-47,415.
4. Bonhoure E., Lauret A., Barnes D.J., Martin C., Malavaud B., Kohama T., et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukaemia cells. Leukemia 2008, 22:971-979.
5. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897.
6. Cuvillier O., Levade T. Sphingosine 1-phosphate antagonises apoptosis of human leukaemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001, 98:2828-2836.
7. De Luca T., Morré D.M., Zhao H., Morré D.J. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors 2005, 25:43-60.
8. Domingo-Domenech J., Oliva C., Rovira A., Codony-Servat J., Bosch M., Filella X., et al. Interleukin 6, a Nuclear-κB target predicts resistance to Docetaxel in hormone-independent prostate cancer and Nuclear Factor-κB inhibition by PS-1145 enhances docetaxel anti-tumour activity. Clin Cancer Res 2006, 12:5578-5586.
9. Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J. Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006, 22:245-257.
10. Fisher K.E., Pop A., Koh W., Anthis N.J., Saunders W.B., Davis G.E. Tumour cell invasion of collagen matrices requires coordinate lipid agonist-induced G protein and membrane-type matrix metalloproteinase-1-dependent signalling. Mol Cancer 2006, 5:69.
11. Gamble J.R., Xia P., Hahn C.N., Drew J.J., Drogemuller C.J., Brown D., et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer 2006, 118:2412-2420.
12. Goetzl E.J., Dolezalova H., Kong Y., Zeng L. Dual mechanism for lysophospholipid induction of proliferation of human breast cancer cells. Cancer Res 1999, 59:4732-4737.
13. Guillermet-Guibert J., Davenne L., Pchejetski D., Saint-Laurent N., Brizuela L., Guilbeau-Frugier C., et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Res 2009, 8:809-820.
14. Jarman K.E., Moretti P.A., Zebol J.R., Pitson S.M. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J Biol Chem 2010, 285:483-492.
15. Kapitonov D., Allegood J.C., Mitchell C., Hait N.C., Almenara J.A., Adams J.K., et al. Targeting sphingosine kinase 1 inhibits Akt signalling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009, 69:6915-6923.
16. Kawamori T., Osta W., Johnson K.R., Pettus B.J., Bielawski J., Tanaka T., et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006, 20:386-388.
17. Kawamori T., Kaneshiro T., Okumura M., Maalouf S., Uflacker A., Bielawski J., et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009, 23:405-414.
18. Kihara A., Anada Y., Igarashi Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. J Biol Chem 2005, 281:4532-4539.
19. Kohno M., Momoi M., Oo M.L., Paik J.H., Lee Y.M., Venkataraman K., et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006, 26:7211-7223.
20. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., et al. Antagonism of sphingosine 1-phosphate receptors by FTY720 inhibits angiogenesis and tumour vascularisation. Cancer Res 2006, 66:221-231.
21. Leclercq T.M., Moretti P.A., Pitson S.M. Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 2011, 30:372-378.
22. Leroux M.E., Auzenne E., Evans R., Hail N., Spohn W., Ghosh S.C., et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2 independent apoptosis in human prostatic adenocarcinoma cells. Prostate 2007, 67:1699-1700.
23. Lim K.G., Tonelli F., Li Z., Lu X., Bittman R., Pyne S., et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011, 286:18633-18640.
24. Long J.S., Edwards J., Watson C., Tovey S., Mair K., Schiff R., et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol Cell Biol 2010, 30:3827-3841.
25. Loveridge C., Tonelli F., Leclercq T.M., Lim K.G., Long J.S., Berdyshev E., et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010, 285:38,841-38,852.
26. Nagaoka Y., Otsuki K., Fujita T., Uesato S. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Bio Pharm Bull 2008, 6:1177-1181.
27. Nyalendo C., Michaud M., Beaulieu E., Roghi C., Murphy G., Gingras D., et al. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumour cell migration. J Biol Chem 2007, 282:15,690-15,699.
28. Park K.S., Kim M.K., Lee H.Y., Kim S.D., Lee S.Y., Kim J.M., et al. S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. Biochem Biophys Res Comm 2007, 356:239-244.
29. Pitson S.M., Moretti P.A., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., et al. Activation of sphingosine kinase 1 by erk-1/2-mediated phosphorylation. EMBO J 2003, 22:5491-5500.
30. Pitson S.M., Xia P., Leclercq T.M., Moretti P.A., Zebol J.R., Lynn H.E., et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005, 201:49-54.
31. Pyne N.J., Pyne S. Sphingosine 1 phosphate and cancer. Nat Rev Cancer 2010, 10:489-503.
32. Ruckäberle E., Rody A., Engels K., Gaetje R., von Minckwitz G., Schiffmann S., et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008, 112:41-52.
33. Schwartz G.K., Ward D., Saltz L., Casper E.S., Spiess T., Mullen E., et al. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997, 3:537-543.
34. Sobue S., Nemoto S., Murakami M., Ito H., Kimura A., Gao S., et al. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukaemia cells. Int J Haematol 2008, 87:266-275.
35. Sukocheva O., Wang L., Verrier E., Vadas M.A., Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signalling pathway. Endocrinology 2009, 150:4484-4492.
36. Tonelli F., Lim K.G., Loveridge C., Long J., Pitson S.M., Tigyi G., et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010, 22:1536-1542.
37. Van Brocklyn J.R., Jackson C.A., Pearl D.K., Kotur M.S., Snyder P.J., Prior T.W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: role of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005, 64:695-705.
38. 3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of Tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010, 177:2205-2215.
39. Wu C.J., Conze D.B., Li T., Srinivasula S.M., Ashwell J.D. Sensing of Lys-63-linked polyubiquitination by NEMO is a key event in NF-κB activation. Nat Cell Biol 2006, 8:398-406.
40. Xia P., Gamble J.R., Wang L., Pitson S.M., Moretti P.A., Wattenberg B.W., et al. An oncogenic role of sphingosine kinase. Curr Biol 2000, 10:1527-1530.
41. Yamashita H., Kitayama J., Shida D., Yamaguchi H., Mori K., Osada M., et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 2006, 130:80-87.